HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Toshiaki Shirakata Selected Research

HLA-A*24:02 antigen

1/2022Cellular and Humoral Immune Responses Induced by an HLA Class I-restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Toshiaki Shirakata Research Topics

Disease

24Neoplasms (Cancer)
01/2022 - 09/2004
5Leukemia
01/2012 - 09/2004
4Wilms Tumor (Wilm's Tumor)
01/2022 - 01/2007
3Myelodysplastic Syndromes (Myelodysplastic Syndrome)
03/2010 - 09/2004
3Hematologic Neoplasms (Hematological Malignancy)
05/2009 - 05/2007
2Ovarian Neoplasms (Ovarian Cancer)
01/2022 - 04/2006
2Hypersensitivity (Allergy)
03/2013 - 09/2009
2Residual Neoplasm
10/2010 - 09/2009
2Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
03/2010 - 09/2004
2Erythema
05/2008 - 09/2004
2Leukopenia
06/2007 - 09/2004
2Lung Neoplasms (Lung Cancer)
01/2007 - 09/2004
1Ascites
01/2022
1Disease Progression
01/2022
1Inflammation (Inflammations)
01/2022
1Melanoma (Melanoma, Malignant)
08/2019
1Salivary Gland Neoplasms (Salivary Gland Cancer)
03/2012
1Carcinoma (Carcinomatosis)
03/2012
1Neoplasm Metastasis (Metastasis)
03/2012
1Pleomorphic Adenoma
03/2012
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
07/2009
1Colonic Neoplasms (Colon Cancer)
05/2009
1Stomach Neoplasms (Stomach Cancer)
05/2009
1Colorectal Neoplasms (Colorectal Cancer)
05/2009
1Carcinogenesis
05/2009
1Gastrointestinal Neoplasms (Gastrointestinal Cancer)
05/2009
1Glioblastoma (Glioblastoma Multiforme)
05/2008
1Multiple Myeloma
12/2007
1Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic)
06/2007
1Pancytopenia
05/2007
1Renal Cell Carcinoma (Grawitz Tumor)
01/2007
1Fibrosarcoma
04/2006

Drug/Important Bio-Agent (IBA)

18Peptides (Polypeptides)IBA
01/2022 - 09/2004
11AntigensIBA
01/2022 - 09/2004
7Protein Subunit VaccinesIBA
01/2022 - 09/2004
7WT1 ProteinsIBA
03/2012 - 09/2004
6Proteins (Proteins, Gene)FDA Link
03/2010 - 10/2004
4VaccinesIBA
01/2022 - 09/2004
4HLA-A Antigens (HLA-A)IBA
11/2008 - 01/2007
3Immunoglobulin G (IgG)IBA
01/2022 - 05/2007
3Cancer VaccinesIBA
01/2022 - 04/2006
2EpitopesIBA
01/2012 - 01/2008
2T-Cell Antigen Receptors (T-Cell Receptor)IBA
08/2011 - 03/2010
2LigandsIBA
03/2008 - 12/2007
2Protein Isoforms (Isoforms)IBA
03/2008 - 04/2006
2Messenger RNA (mRNA)IBA
06/2007 - 10/2004
1HLA-A*24:02 antigenIBA
01/2022
1Serum AlbuminIBA
01/2022
1C-Reactive ProteinIBA
01/2022
1Cell Wall SkeletonIBA
08/2019
1Monatide (IMS 3015)IBA
03/2012
1Histocompatibility Antigens Class IIBA
01/2012
1InterferonsIBA
01/2012
1Aurora Kinase AIBA
01/2012
1Neoplasm Antigens (Tumor Antigens)IBA
08/2011
1Imatinib Mesylate (Gleevec)FDA Link
10/2010
1multiple myeloma M-proteinsIBA
09/2009
1Peptide Elongation Factors (Elongation Factor)IBA
05/2009
1Phosphotransferases (Kinase)IBA
05/2009
1Peptide Elongation Factor 2 (EF-2)IBA
05/2009
1Small Interfering RNA (siRNA)IBA
05/2009
1Etoposide (VP 16)FDA LinkGeneric
03/2008
1Doxorubicin (Adriamycin)FDA LinkGeneric
03/2008
1HLA-A*02:01 antigenIBA
01/2008
1AntibodiesIBA
05/2007
1Immunoglobulin IsotypesIBA
05/2007
1Immunoglobulin M (IgM)IBA
05/2007
1GemcitabineFDA Link
05/2007
1RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
10/2004
1Tumor Biomarkers (Tumor Markers)IBA
09/2004

Therapy/Procedure

16Immunotherapy
08/2019 - 09/2004
8Therapeutics
08/2019 - 04/2006
3Drug Therapy (Chemotherapy)
01/2022 - 05/2007